Business Description
Viridian Therapeutics Inc
NAICS : 325199
SIC : 2834
ISIN : US60463E1038
Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 22.68 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 7.6 | |||||
| Beneish M-Score | -2.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -71.3 | |||||
| 3-Year EBITDA Growth Rate | 44.6 | |||||
| 3-Year EPS without NRI Growth Rate | 22.7 | |||||
| 3-Year FCF Growth Rate | 21 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 4.57 | |||||
| 9-Day RSI | 12.79 | |||||
| 14-Day RSI | 21.8 | |||||
| 6-1 Month Momentum % | 60.8 | |||||
| 12-1 Month Momentum % | -38.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.26 | |||||
| Quick Ratio | 18.26 | |||||
| Cash Ratio | 17.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -133.7 | |||||
| Shareholder Yield % | -1.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -81035.03 | |||||
| Net Margin % | -75711.47 | |||||
| FCF Margin % | -58938.85 | |||||
| ROE % | -66.52 | |||||
| ROA % | -59.66 | |||||
| ROIC % | -2128.29 | |||||
| ROC (Joel Greenblatt) % | -6961.19 | |||||
| ROCE % | -63.72 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1876.2 | |||||
| PB Ratio | 2.91 | |||||
| Price-to-Tangible-Book | 2.91 | |||||
| EV-to-EBIT | -2.41 | |||||
| EV-to-Forward-EBIT | -3.66 | |||||
| EV-to-EBITDA | -2.41 | |||||
| EV-to-Forward-EBITDA | -3.66 | |||||
| EV-to-Revenue | 1809.09 | |||||
| EV-to-Forward-Revenue | 3890.79 | |||||
| EV-to-FCF | -3.07 | |||||
| Price-to-Median-PS-Value | 211.67 | |||||
| Price-to-Net-Current-Asset-Value | 2.96 | |||||
| Price-to-Net-Cash | 1.6 | |||||
| Earnings Yield (Greenblatt) % | -41.49 | |||||
| FCF Yield % | -23.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRDN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viridian Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.314 | ||
| EPS (TTM) ($) | -5.32 | ||
| Beta | 0.76 | ||
| Volatility % | 62.47 | ||
| 14-Day RSI | 21.8 | ||
| 14-Day ATR ($) | 0.930214 | ||
| 20-Day SMA ($) | 15.849 | ||
| 12-1 Month Momentum % | -38.07 | ||
| 52-Week Range ($) | 10.925 - 28.99 | ||
| Shares Outstanding (Mil) | 62.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viridian Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viridian Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Viridian Therapeutics Inc Frequently Asked Questions
What is Viridian Therapeutics Inc(VRDN)'s stock price today?
The current price of VRDN is $12.70. The 52 week high of VRDN is $28.99 and 52 week low is $10.93.
When is next earnings date of Viridian Therapeutics Inc(VRDN)?
The next earnings date of Viridian Therapeutics Inc(VRDN) is 2024-05-09 Est..
Does Viridian Therapeutics Inc(VRDN) pay dividends? If so, how much?
Viridian Therapeutics Inc(VRDN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers